InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: jondoeuk post# 209

Saturday, 05/21/2016 4:19:09 PM

Saturday, May 21, 2016 4:19:09 PM

Post# of 977
PLX3397 was well tolerated and readily crossed the blood-tumor barrier but showed no efficacy in a phase II study in patients with recurrent GB.

It can't be used with Keytruda if it reduces TILs.

We also reveal a role for PLX3397 in reducing tumor-infiltrating lymphocytes, and interestingly, this feature was rescued by the co-administration of PLX4720.

http://www.ncbi.nlm.nih.gov/pubmed/27141346